# 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

> **NCT04605614** · PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **RADIATION:** Copper Cu 64-DOTA-pembrolizumab
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT04605614
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-15
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow accruals
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605614, "64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04605614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*